Answer
In patients with relapsed or refractory acute lymphoblastic leukaemia, the terminal elimination half-life of inotuzumab ozogamicin at the end of Cycle 4 was approximately 12.3 days.
Sources for this answer
- BESPONSA 1 mg powder for concentrate for solution for infusionPfizer Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 12Document updated
Sources checked